Abstract:Genomic alterations in cancer cells result in vulnerabilities that clinicians can exploit using molecularly targeted drugs, guided by knowledge of the tumour genotype. However, the selective activity of these drugs exerts an evolutionary pressure on cancers that can result in the outgrowth of resistant clones. Use of rational drug combinations can overcome resistance to targeted drugs, but resistance may eventually develop to combinatorial therapies. We selected MAPK- and PI3K-pathway inhibition in colorectal cancer as a model system to dissect out mechanisms of resistance. We focused on these signalling pathways because they are frequently activated in colorectal tumours, have well-characterised mutations and are clinically relevant. By treating a panel of 47 human colorectal cancer cell lines with a combination of MEK- and PI3K-inhibitors, we observe a synergistic inhibition of growth in almost all cell lines. Cells with KRAS mutations are less sensitive to PI3K inhibition, but are particularly sensitive to the combined treatment. Colorectal cancer cell lines with inherent or acquired resistance to monotherapy do not show a synergistic response to the combination treatment. Cells that acquire resistance to an MEK–PI3K inhibitor combination treatment still respond to an ERK–PI3K inhibitor regimen, but subsequently also acquire resistance to this combination treatment. Importantly, the mechanisms of resistance to MEK and PI3K inhibitors observed, MEK1/2 mutation or loss of PTEN, are similar to those detected in the clinic. ERK inhibitors may have clinical utility in overcoming resistance to MEK inhibitor regimes; however, we find a recurrent active site mutation of ERK2 that drives resistance to ERK inhibitors in mono- or combined regimens, suggesting that resistance will remain a hurdle. Importantly, we find that the addition of low concentrations of the BCL2-family inhibitor navitoclax to the MEK–PI3K inhibitor regimen improves the synergistic interaction and blocks the acquisition of resistance.

MEK inhibitor resistance mechanisms and recent developments in combination trials

Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.

Abstract 1947: Studies on pMEK inhibitors for the treatment of RAS-mutant cancers as a single agent or combinations

The Overview of Mitogen-activated Extracellular Signal-Regulated Kinase (Mek)-Based Dual Inhibitor in the Treatment of Cancers.

Nanosized Modification Strategies for Improving the Antitumor Efficacy of MEK Inhibitors

Targeting MEK in non-small cell lung cancer

Data from ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors

Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity

MEK inhibitors in oncology: a patent review and update (2016 – present)

The MEK/ERK Network as a Therapeutic Target in Human Cancer

Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers

Advances in the Research of Raf Kinase Inhibitors and Drug Resistance Mechanisms

Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer

Targeted Therapy in Melanoma and Mechanisms of Resistance

Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers

Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma

Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer

Developments in Mitogen-Induced Extracellular Kinase 1 Inhibitors and Their Use in the Treatment of Disease

Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma

Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies

Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy